Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None USD 0.00(0%)
Last update at 2026-06-18T21:24:27.677389Z
Market Cap
38.97M

Momentum Score

…

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.51
Low
2.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
9.03M
Revenue Per Share
0.37
Gross Profit TTM
29.26M
Debt / Equity
0.10
ROE
-65.42%
Net Debt
-18.50M
ROCE
-19.69%
Diluted EPS TTM
-1.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.37M -10.28M -28.40M -19.92M -17.00M
Minority interest - - - 0.00M 0.00M
Net income -8.33M -9.98M -28.88M -19.96M -17.05M
Selling general administrative 4.99M 2.82M 3.62M 2.73M 3.19M
Selling and marketing expenses 0.08M 0.12M 0.65M 0.26M -
Gross profit 29.26M 9.10M 7.46M 10.25M 1.28M
Reconciled depreciation 21.85M 3.43M 6.47M 2.37M 1.57M
Ebit -8.71M -9.92M -27.98M -19.47M -22.51M
Ebitda 13.14M -6.49M -21.50M -17.10M -15.29M
Depreciation and amortization 21.85M 3.43M 6.47M 2.37M -
Non operating income net other - - - 0.00M 0.00M
Operating income -8.73M -9.98M -28.66M -20.16M -17.82M
Other operating expenses 39.97M 20.45M 32.08M 30.79M 0.18M
Interest expense 0.66M 0.36M 0.43M 0.45M 0.15M
Tax provision -1.04M -0.30M 0.47M 0.04M 0.04M
Interest income 0.03M 0.02M 0.06M 0.16M 0.22M
Net interest income -0.63M -0.28M 0.21M 0.31M 0.64M
Extraordinary items - - - 0.00M 0.00M
Non recurring - - - 0.00M 0.00M
Other items - - - 0.00M 0.00M
Income tax expense -1.04M -0.30M 0.47M 0.04M -0.45M
Total revenue 31.25M 10.46M 8.75M 10.63M 7.58M
Total operating expenses 37.99M 19.09M 30.79M 30.41M 25.40M
Cost of revenue 1.98M 1.36M 1.29M 0.38M 6.30M
Total other income expense net -0.65M -0.30M 0.26M 0.24M 2.85M
Discontinued operations - - - 0.00M 0.00M
Net income from continuing ops -8.33M -9.98M -28.88M -19.96M -17.05M
Net income applicable to common shares -8.33M -9.98M -28.88M -19.96M -21.23M
Preferred stock and other adjustments - - - 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 51.68M 59.47M 74.75M 109.22M 129.59M
Intangible assets 9.75M 30.11M 31.63M 33.49M 34.01M
Other current assets 0.02M 0.02M 0.29M 0.53M 2.70M
Total liab 14.65M 14.65M 21.60M 27.39M 22.16M
Total stockholder equity 37.03M 44.82M 53.15M 81.82M 107.42M
Deferred long term liab - - - 0.00M 0.00M
Other current liab 0.96M 0.98M 2.66M 3.18M 5.61M
Common stock 24.56M 24.56M 24.56M 24.56M 24.56M
Capital stock 24.56M 24.56M 24.56M 24.56M 24.56M
Retained earnings -470.01M -461.68M -451.70M -422.83M -402.86M
Other liab 4.49M 3.48M 7.47M 12.24M 12.02M
Good will - - 0.00M 2.21M 2.21M
Other assets 0.29M 0.29M 0.29M 3.52M 1.48M
Cash 22.22M 22.42M 30.03M 34.68M 27.41M
Total current liabilities 7.42M 8.03M 10.13M 10.22M 8.82M
Current deferred revenue 4.84M 5.67M 5.88M 4.91M -
Net debt -18.50M -18.39M -24.88M -29.63M -
Short term debt 0.98M 0.89M 1.16M 0.76M 0.00M
Short long term debt - - - 0.00M 0.00M
Short long term debt total 3.73M 4.02M 5.15M 5.05M -
Other stockholder equity 482.48M 481.94M 480.29M 480.09M 481.56M
Property plant equipment 4.39M 4.90M 6.88M 8.82M 4.26M
Total current assets 37.25M 24.16M 32.70M 57.73M 57.52M
Long term investments - - - 0.00M 87.42M
Net tangible assets 27.28M 14.70M 21.52M 46.12M 67.02M
Short term investments 11.00M - - 20.00M 24.00M
Net receivables 3.24M 1.33M 1.96M 2.02M 3.49M
Long term debt - - - 0.00M 0.00M
Inventory - - - 0.00M 2.62M
Accounts payable 0.63M 0.50M 0.43M 1.37M 1.36M
Total permanent equity - - - 0.00M 0.00M
Noncontrolling interest in consolidated entity - - - 0.00M 0.00M
Temporary equity redeemable noncontrolling interests - - - 0.00M 0.00M
Accumulated other comprehensive income - - - 0.00M 0.00M
Additional paid in capital - - - 0.00M 0.00M
Common stock total equity - - - 0.00M 0.00M
Preferred stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - 0.00M 0.00M
Treasury stock - - - 0.00M 0.00M
Accumulated amortization - - - 0.00M 0.00M
Non currrent assets other 0.29M 0.29M 3.54M 23.37M 1.29M
Deferred long term asset charges - - - 0.00M 0.00M
Non current assets total 14.43M 35.31M 42.05M 51.49M 67.39M
Capital lease obligations 3.73M 4.02M 5.15M 5.05M 1.51M
Long term debt total - - - 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -12.01M 4.12M 20.58M 24.59M -19.46M
Change to liabilities 0.14M 0.07M -0.94M 0.01M 0.63M
Total cashflows from investing activities -12.01M 4.03M 21.12M 24.17M -19.47M
Net borrowings -0.28M -1.03M -0.83M -0.49M -0.73M
Total cash from financing activities -0.28M -1.03M -0.83M -0.47M 29.30M
Change to operating activities 1.26M -5.66M -4.57M 0.80M 3.43M
Net income -9.37M -10.28M -28.40M -19.92M -21.23M
Change in cash -0.19M -7.62M -4.65M 7.27M -0.32M
Begin period cash flow 22.42M 30.03M 34.68M 27.41M 27.72M
End period cash flow 22.22M 22.42M 30.03M 34.68M 27.41M
Total cash from operating activities 11.98M -10.75M -24.79M -16.42M -10.14M
Issuance of capital stock - - 0.00M 0.02M 32.44M
Depreciation 21.85M 3.43M 6.47M 2.37M 1.57M
Other cashflows from investing activities - - 0.00M 0.00M 0.00M
Dividends paid - - - 0.00M 0.00M
Change to inventory - - 0.00M 0.30M 0.43M
Change to account receivables -2.28M 0.91M 2.65M 0.34M 0.60M
Sale purchase of stock - - - 0.00M 0.00M
Other cashflows from financing activities -12.01M 4.03M -0.54M -0.49M -2.41M
Change to netincome -0.66M 0.48M 2.69M -0.29M 4.42M
Capital expenditures 1.01M 0.12M 0.48M 1.43M 1.01M
Change receivables - - - 0.00M 0.00M
Cash flows other operating - - - 0.00M 0.00M
Exchange rate changes - - - 0.00M 0.00M
Cash and cash equivalents changes - - - 0.00M 0.00M
Change in working capital -0.89M -4.68M -2.86M 1.46M 5.09M
Stock based compensation 0.35M 0.65M 0.66M 0.49M -
Other non cash items 0.28M 0.35M 0.36M 0.29M -0.07M
Free cash flow 10.97M -10.88M -25.27M -17.85M -11.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Medigene AG

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Lochhamer Strasse 11, Munich, Germany, 82152

49 89 2000 330

87

Name Title Year Born
Dr. Dolores J. Schendel Chief Scientific Officer, Member of Exec. Management Board and Head of R&D NA
Dr. Selwyn Ho MB BS, MBBS CEO & Member of Exec. Management Board 1971
Dr. Ernst-Ludwig Winnacker Co-Founder & Chairman Scientific Advisory Board 1941
Dr. Birger Kohlert Chief Financial Officer NA
Dr. Rene Goedkoop Acting Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…